BCLI
NASDAQBrainstorm Cell Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks310%
2026-03-012026-08-23
Mix1890d
- Insider8(44%)
- SEC Filings5(28%)
- Leadership3(17%)
- Other2(11%)
Latest news
25 items- PRBrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel SessionsExecutive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.Pitts to moderate expert sessions on Translational Pharmaceutical Innovation and the Emerging Roles of Pharmacists.President and CEO Chaim Lebovits and executive team to conduct strategic regional partnership and healthcare investor meetings in Dubai.DUPHAT to take place August 25 to 27, 2026, at the Dubai World Trade Centre.NEW YORK, Aug. 24, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) ("BrainStorm" or the "Company"), a developer of cell therapies for neurodegenerative diseas
- SECSEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc.10-Q - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- SECBrainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- PRBrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateNEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "The recent appointment of Peter Pitts as Executive Chairman represents an import
- SECBrainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- INSIDERDirector Frenkel Jacob A was granted 100,000 shares, increasing direct ownership by 41% to 343,777 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Executive Chairman Pitts Peter Joe4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- PRBrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanProfessor Jacob Frenkel Transitions to Senior AdvisorPeter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidateNEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team. Peter J. Pitts, co-founder of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, has been named Executive Chairman
- INSIDERSEC Form 3 filed by new insider Pitts Peter Joe3 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- SECSEC Form EFFECT filed by Brainstorm Cell Therapeutics Inc.EFFECT - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- PRBrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative MedicineFormer FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicineNEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the u
- INSIDERPresident & CEO Lebovits Chaim was granted 1,800,000 shares, increasing direct ownership by 896% to 2,000,960 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDEREVP & Chief Business Officer Yablonka Uri was granted 150,000 shares, increasing direct ownership by 219% to 218,464 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDEROfficer Patlis Alla was granted 100,000 shares, increasing direct ownership by 225% to 144,349 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERDirector Frenkel Jacob A was granted 200,000 shares, increasing direct ownership by 457% to 243,777 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERDirector Arbel Irit was granted 120,000 shares, increasing direct ownership by 292% to 161,054 units (SEC Form 4)4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- SECBrainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- PRBrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsFormer Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol AssessmentNEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately. Mr. Pitts is a globally recognized expert in healthcare policy, regulatory science, and U.S. Food and Drug Administration (FDA) governance. He previously served as A
- INSIDERSEC Form 4 filed by Director Bairu Menghisteab4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Director Polverino Anthony J.4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Director Hartounian Hartoun4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Director Lindborg Stacy4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Director Naor Nir4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- INSIDERSEC Form 4 filed by Director Dagher Ibrahim B.4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
- PRBrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE TrialNEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing:The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. Investors will also receive 120% warrant coverage with an exercise price of $1.45 per share and a five-year term from the date of issuance. Two of t
BCLI FAQ
5 questionsWhat does Brainstorm Cell Therapeutics Inc. do?
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III...Where does BCLI stock trade?
Brainstorm Cell Therapeutics Inc. (BCLI) is listed on NASDAQ.What sector and industry is BCLI in?
Brainstorm Cell Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to BCLI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare BCLI side-by-side with any of them on Quantisnow.How can I track BCLI on Quantisnow?
Quantisnow aggregates Brainstorm Cell Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCLI to receive live email and push alerts on every new disclosure.